Istiratumab
- Generic Name
- Istiratumab
- Drug Type
- Biotech
- CAS Number
- 1509928-04-4
- Unique Ingredient Identifier
- XLR461MD3M
- Background
Istiratumab is under investigation in clinical trial NCT02399137 (A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer).
Phase 1 Combination Study of MM-151 With MM-121, MM-141, or Trametinib
Phase 1
Terminated
- Conditions
- Colorectal CancerNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and Neck
- Interventions
- First Posted Date
- 2015-09-02
- Last Posted Date
- 2017-09-05
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 5
- Registration Number
- NCT02538627
- Locations
- 🇺🇸
Washington University, Saint Louis, Missouri, United States
🇺🇸Vanderbilt, Nashville, Tennessee, United States
🇺🇸Northside Hospital, Sandy Springs, Georgia, United States
A Phase 2 Study of MM-141 Plus Nab-paclitaxel and Gemcitabine in Front-line Metastatic Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Interventions
- First Posted Date
- 2015-03-26
- Last Posted Date
- 2018-09-18
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 88
- Registration Number
- NCT02399137
- Locations
- 🇺🇸
Reliant Medical Group, Inc., Worcester, Massachusetts, United States
🇺🇸Banner MD Anderson Cancer Ctr., Gilbert, Arizona, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
A Phase 1 Study of MM-141 in Patients With Advanced Solid Tumors
- First Posted Date
- 2012-11-26
- Last Posted Date
- 2016-08-04
- Lead Sponsor
- Merrimack Pharmaceuticals
- Target Recruit Count
- 42
- Registration Number
- NCT01733004
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath